Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 370Lymphoma, Non-Hodgkin 348Leukemia, Lymphocytic, Chronic, B-Cell 322Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Lymphoma, Large B-Cell, Diffuse 244Lymphoma, Follicular 236Leukemia 198Hodgkin Disease 171Lymphoma, Mantle-Cell 164Leukemia, Myeloid, Acute 160Multiple Myeloma 134Myelodysplastic Syndromes 130Recurrence 125Burkitt Lymphoma 123Lymphoma, B-Cell, Marginal Zone 120Lymphoma, T-Cell, Cutaneous 92Neoplasms 82Mycosis Fungoides 82Lymphoma, B-Cell 82Waldenstrom Macroglobulinemia 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 70Sezary Syndrome 67Lymphoma, Large-Cell, Immunoblastic 65Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 57Lymphoma, Large-Cell, Anaplastic 54Neoplasms, Plasma Cell 52Myeloproliferative Disorders 52Primary Myelofibrosis 46Hematologic Neoplasms 44Blast Crisis 43

Interventions

ibrutinib 1daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hypergammaglobulinemia × Lymphoid × Clear all
NCT03679624 2023-10-23

Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia

Weill Medical College of Cornell University

Phase 2 Terminated
1 enrolled 8 charts
Lymphoid

Hypergammaglobulinemia, Waldenstrom Macroglobulinemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡